Ocular drug development - Future Directions

By Sherris David  

Angiogenesis, Vol. 10, Iss. 2, 2007-06 ,pp. : 71-76

Springer Publishing Company

Access to resources Recommend Favorite

A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents

By Mahan Charles  

Journal of Thrombosis and Thrombolysis, Vol. 37, Iss. 3, 2014-04 ,pp. : 271-278

Springer Publishing Company

Access to resources Recommend Favorite

Anti-thrombotic Efficacies of Enoxaparin, Dalteparin, and Unfractionated Heparin in Venous Thrombo-embolism

By Morris T.A.   Marsh J.J.   Konopka R.   Pedersen C.A.   Chiles P.G.  

Thrombosis Research, Vol. 100, Iss. 3, 2000-11 ,pp. : 185-194

Elsevier

Access to resources Recommend Favorite

The Role of Low-Molecular-Weight Heparins in Arterial Diseases - Optimizing Antithrombotic Therapy

By Cohen M.  

Thrombosis Research, Vol. 100, Iss. 2, 2000-10 ,pp. : 131-139

Elsevier

Access to resources Recommend Favorite

Signs of thrombin generation in pediatric cardiac catheterization with unfractionated heparin bolus or subcutaneous low molecular weight heparin for antithrombotic cover

By Roschitz B.   Beitzke A.   Gamillscheg A.   Sudi K.   Koestenberger M.   Leschnik B.   Muntean W.  

Thrombosis Research, Vol. 111, Iss. 6, 2003-01 ,pp. : 335-341

Elsevier

Access to resources Recommend Favorite